Treatment with navenibart, or STAR-0215, safely reduced the rate of monthly swelling attacks by 90% to 95% in people with hereditary angioedema (HAE) when the therapy was given once or twice over six months, data from the completed Phase 1/2 ALPHA-STAR clinical trial shows.
Stroke patients treated with alteplase, a medication used to dissolve blood clots, are at an increased risk of developing angioedema, a retrospective study has found. Being female, using ACE or angiotensin-converting enzyme inhibitors, and having high blood pressure were all identified as “significant risk factors for angioedema among alteplase-treated…
Orladeyo (berotralstat), an oral therapy designed to reduce or prevent hereditary angioedema (HAE) attacks, is now available in Ireland. The Irish Health Services Executive (HSE) recommended Orladeyo as a prophylactic, or preventive, treatment for HAE in adults and adolescents, ages 12 and older. Biocryst Pharmaceuticals, the company marketing…
An 80-year-old man in Texas developed angioedema thought to be triggered by the antipsychotic therapy risperidone, according to a new case study highlighting a possible risk with the use of this medication. The researchers noted that “only 10 cases listing risperidone as the only probable causative agent for angioedema…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to navenibart — the new generic name of Astria Therapeutics’ experimental therapy STAR-0215 — as a treatment for hereditary angioedema (HAE).
People with hereditary angioedema (HAE) in Japan with access to on-demand therapies alone can have a high rate of attack frequency — weekly or monthly — that associates with a poorer quality of life, a study in that country reports. Patients’ functioning, fears, and feelings of shame significantly linked…
Race and geographic disparities are common in clinical trials of hereditary angioedema (HAE), with non-white patients and countries outside the U.S. and Europe underrepresented, a study by an international team of researchers has found. While participation from European and Asian nations in HAE trials has increased significantly in the…
People with hereditary angioedema (HAE) typically experience a markedly delayed diagnosis — from three to 26 years following the onset of symptoms — that results in a greater disease burden for patients, with growing HAE-related expenses from hospitalizations, medications, potentially unnecessary surgeries, and a plethora of doctor visits, according…
Children in Egypt with hereditary angioedema (HAE) wait an average of three years to be diagnosed, according to a small study. Delayed diagnosis was common despite more than half the children in the study having a family history of the disease. About half of the 18 patients in the study…
Otsuka Pharmaceutical has obtained exclusive rights to commercialize donidalorsen for hereditary angioedema (HAE) in the Asia-Pacific region. The deal is an extension of a previous license agreement that granted Otsuka the rights to commercialize the therapy in Europe. Ionis Pharmaceuticals, the therapy’s original developer, retains…
Get regular updates to your inbox.